Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of mipomersen in familial or severe hypercholesterolemia
2005-003450-10Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2008
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mipomersen in familial hypercholesterolemia (FH) and hypercholesterolemia, sponsored by Sanofi. Primary endpoint: Primary safety endpoints. Started May 2008; status: completed.
02
Drugs
mipomersen
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on 2005-003450-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003450-10.